about
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityDefective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage.Cardiotoxic effects of anthracycline-taxane combinations.Redox cycling of iron and lipid peroxidation.The role of an endogenous nonheme iron in microsomal redox reactions.Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.An introduction to the metabolic determinants of anthracycline cardiotoxicity.Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.The concomitant management of cancer therapy and cardiac therapy.Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase.The anthracyclines: when good things go bad.NADPH- and adriamycin-dependent microsomal release of iron and lipid peroxidation.The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.Pharmacological foundations of cardio-oncology.Effect of reactive oxygen species on iron regulatory protein activity.Superoxide-dependent lipid peroxidation and vitamin E content of microsomes from hepatomas with different growth rates.tert-butyl hydroperoxide-dependent microsomal release of iron and lipid peroxidation. I. Evidence for the reductive release of nonheme, nonferritin irontert-butyl hydroperoxide-dependent microsomal release of iron and lipid peroxidation. II. Evidence for the involvement of nonheme, nonferritin iron in lipid peroxidationRestoration of hydroperoxide-dependent lipid peroxidation by 3-methylcholanthrene induction of cytochrome P-448 in hepatoma microsomesAdriamycin-dependent release of iron from microsomal membranesSuperoxide-dependent redox cycling of citrate-Fe3+: evidence for a superoxide dismutaselike activityAn investigation into the mechanism of citrate-Fe2+-dependent lipid peroxidationAnthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metaboliteDoxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reductionDefective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapiesDoxorubicin degradation in cardiomyocytesCardiotoxicity of antitumor drugsBeyond poisons and problems: toxicology in ItalyPaclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapiesPharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicinPharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin
P50
Q29614981-6F40449D-DFDB-46C7-A49C-90C6B358C94CQ33232092-47B1DD42-C48D-4486-8D6B-23A4101DC535Q33689816-B93108E8-9787-4588-A256-03D7E4487B08Q34679185-5CAB1E50-763C-4F5C-B249-D5A45559EF59Q35194442-C4D91211-A322-4C92-BCC2-1201F0D4DE34Q35232989-3D9FC2CB-322B-49A1-86AB-A479CFB9282BQ35671142-27C3BAC7-E11A-490C-82F2-F26833005923Q35708054-776E12DD-97CE-4AB1-A7C4-1764BDBDD353Q36891719-50C8984E-20CE-49D4-B4FB-D7CFA5C3709FQ37642751-B67FE84D-021D-4283-854E-1AFA49F5B450Q37871666-0443F5E2-725F-43B1-B030-C77D00585F1DQ38321789-66532F19-9EDB-4899-A773-8AA124E0DFE6Q38977933-19FC83C6-AC01-48FB-A5A6-0C185CE3C813Q38998367-440B603E-FF40-4145-9093-99F3C5E0EFE1Q40727934-5F52F44E-93D6-4B4E-BDB8-8EF317C92021Q42163160-640EE835-7CEE-4BF0-AA9F-3EBBA15DFEE3Q43763829-3A8793D1-C981-4116-9628-53ED9A98ACF7Q43906042-6AC1128D-0153-444E-8688-0626775FFED3Q44578142-E884DFA0-25C4-4204-8719-B251F3655560Q44666436-62C72241-C86A-46E3-9E12-2FF8803BBC67Q44764058-201D8835-32A4-4BFB-B6BB-2194C18460ADQ46035361-20DE8046-A324-4D6E-A8D4-2A6283E64E35Q47617394-CAFE21FA-97A7-4A34-845A-13EFFB543481Q47823897-2D578215-6EF1-45F5-872F-43EC12F95B6AQ54451299-166F8450-E6F8-488E-BFFA-A084F46CF36FQ69673771-DB7B241B-E4EA-4AB1-AFBD-6B499F83AF7CQ69673776-D5869EC5-606A-4EE8-820F-CFFEF609DBACQ69690723-8741AB75-60A6-4DBC-A209-9C313E6F76B0Q69938658-12CF78E5-B725-4D12-93B8-7B93D4555144Q70164485-5A8A6C96-C332-4940-8869-D71B1194D071Q70373798-224C3813-3E75-4F3B-A189-EAB70924DF86Q73313569-8B3F3E52-B22C-4B3B-81B9-B3EE99CA46D7Q73798007-AC41326A-879E-4915-ACBB-872DB91F1512Q79393786-11846231-40C0-443D-AF73-139844DFB87BQ80236768-F5AAC188-7B01-431A-8AB4-4BA4C22D794AQ80982459-FD1362E9-A98F-4547-B7BE-46338AEDE54EQ81112723-5B9DC34B-9B63-40D2-820B-438F57402E37Q83154015-1DD1AE09-23BC-423C-9332-11B58EC7FDE9Q83455929-CE0D94FF-79CD-4769-B039-EB7DFD04E882Q83455932-4DC097EF-8497-4650-BC54-27B217277BDA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giorgio Minotti
@ast
Giorgio Minotti
@en
Giorgio Minotti
@es
Giorgio Minotti
@nl
Giorgio Minotti
@sl
type
label
Giorgio Minotti
@ast
Giorgio Minotti
@en
Giorgio Minotti
@es
Giorgio Minotti
@nl
Giorgio Minotti
@sl
prefLabel
Giorgio Minotti
@ast
Giorgio Minotti
@en
Giorgio Minotti
@es
Giorgio Minotti
@nl
Giorgio Minotti
@sl
P106
P1153
7003569947
P31
P496
0000-0002-5678-6175